While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...

Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ultralong-acting challenger to candidates in development at AbbVie, Eli Lilly ...

(RTTNews) - Metsera, Inc. (MTSR) posted a net loss of $76.6 million for the quarter ended March 31, 2025, compared to a loss of $19.9 million for the quarter ended March 31, 2024. Net loss per ...

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, ...

Furthermore, Metsera’s IPO opened 42% higher on the Nasdaq Global Select Market, with several financial firms acting as joint bookrunners for the offering. These developments indicate a strong ...